Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 Terminated
5 enrolled 13 charts
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
Phase 2 Terminated
15 enrolled 11 charts
CPIT001
Phase 1/2 Terminated
46 enrolled 13 charts
CMP-001 for Relapsed and Refractory Lymphoma
Phase 1/2 Terminated
14 enrolled 11 charts
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Phase 1/2 Terminated
20 enrolled 34 charts
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Phase 2 Terminated
10 enrolled 11 charts
ZUMA-25
Phase 2 Terminated
19 enrolled 28 charts
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Phase 2 Terminated
21 enrolled 11 charts
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
Phase 2 Terminated
5 enrolled 11 charts
EXPAND
Phase 2 Terminated
2 enrolled 8 charts
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Phase 2 Terminated
18 enrolled 11 charts
HeartPhone Cancer Survivors Trial 2019
Phase 1/2 Terminated
2 enrolled 6 charts
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
Phase 2 Terminated
22 enrolled 20 charts
Impact of Respiratory Training in Lymphoma Survivors
Phase NA Terminated
1 enrolled 2 charts
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Phase 1/2 Terminated
8 enrolled 11 charts
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
Phase 2 Terminated
5 enrolled 11 charts
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Phase 1 Terminated
69 enrolled 47 charts
topMIND
Phase 1/2 Terminated
54 enrolled 23 charts
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 2 Terminated
12 enrolled 10 charts
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Phase 2 Terminated
8 enrolled 10 charts
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Phase 2 Terminated
14 enrolled 15 charts
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
Phase 2 Terminated
2 enrolled 10 charts
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Phase 2 Terminated
30 enrolled 10 charts
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Phase 2 Terminated
9 enrolled 12 charts
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Phase 1/2 Terminated
93 enrolled 27 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
Phase 1/2 Terminated
8 enrolled 8 charts
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Phase 2 Terminated
4 enrolled 7 charts
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Phase 1/2 Terminated
9 enrolled 20 charts
Radiation Post-CAR T in Refractory Lymphoma
Phase NA Terminated
3 enrolled 9 charts
A Study of Isatuximab-based Therapy in Participants With Lymphoma
Phase 1/2 Terminated
58 enrolled 37 charts
ISAKIDS
Phase 2 Terminated
67 enrolled 25 charts
Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia
Phase 2 Terminated
10 enrolled 5 charts
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1/2 Terminated
6 enrolled 17 charts
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
Phase 1 Terminated
15 enrolled 12 charts
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Phase 2 Terminated
255 enrolled 29 charts
LuminICE-203
Phase 2 Terminated
25 enrolled 21 charts
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 1/2 Terminated
4 enrolled 8 charts
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Phase NA Terminated
2,117 enrolled 6 charts
PROACT
Phase 2 Terminated
49 enrolled 12 charts
MK-2118-001
Phase 1 Terminated
140 enrolled 37 charts
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Phase 2 Terminated
18 enrolled 14 charts
ALEXANDER
Phase 1/2 Terminated
52 enrolled 29 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Phase 1 Terminated
53 enrolled 27 charts
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1 Terminated
13 enrolled 10 charts
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Phase 1 Terminated
203 enrolled 43 charts
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Phase 1/2 Terminated
196 enrolled 28 charts
Phase l/II Study of Ruxolitinib for Acute Leukemia
Phase 1/2 Terminated
27 enrolled 6 charts
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Phase 2 Terminated
11 enrolled 13 charts